Frontiers in Oncology最新文献

{"title":"Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma.","authors":"Chiara Deiana, Andrea Palloni, Mirta Mosca, Francesco Vasuri, Stefano Chillotti, Simona Tavolari, Dario De Biase, Giorgio Frega, Elisa Giovannetti, Giovanni Brandi","doi":"10.3389/fonc.2025.1459705","DOIUrl":"10.3389/fonc.2025.1459705","url":null,"abstract":"<p><p>Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer, with intermediate biological characteristics between hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Given its rarity and the lack of robust data from randomized clinical trials, treatment is not standardized, and the choice on how to best manage the disease is left to the expertise of each institution. In the metastatic setting, given the more aggressive behavior of the CCA component, the usual approach is to start treatment with chemotherapy instead of tyrosine-kinase inhibitors (TKIs). We present a case report on a Caucasian male with a poor response to first-line treatment with chemotherapy directed against CCA, but with an excellent and long overall survival (OS) of 71 months, thanks to HCC-directed treatment with TKI. Here, we highlight the difficulty in selecting an appropriate treatment upfront for this rare cancer and we also discuss future perspectives regarding predictive tools, especially considering the recent genomic analysis of cHCC-CCA, and regarding the potential use of immunotherapy and target therapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1459705"},"PeriodicalIF":3.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IGV-001 cellular immunotherapy for newly diagnosed glioblastoma: overcoming the logistic challenge.","authors":"Eric T Wong, Deus Cielo, Konstantina Svokos, Curt Doberstein, Prakash Sampath, John E Donahue, Michael Punsoni, Nuno Rodrigues, Francesca Rothell, Robert Edwards, Elaina Wang, Tori Riccelli, Carlin Chuck, Elias A Shaaya, Rahul Sastry, Rohaid Ali, Belinda Shao, Hael Abdulrazeq, Felicia W Sun, Joshua Feler, Santos E Santos Fontánez, Natalie Amaral Nieves, Cody Dobertsein, Jennifer Dailey, Christine Yu, Sasmit Sarangi, Heinrich Elinzano, Jerrold L Boxerman, Esther Yu, Howard Safran, Attila A Seyhan, Wafik S El-Deiry, Sharonda Keith, Ziya L Gokaslan, Clark C Chen, Athar Malik","doi":"10.3389/fonc.2025.1556450","DOIUrl":"10.3389/fonc.2025.1556450","url":null,"abstract":"<p><strong>Background: </strong>IGV-001 is a type of cellular immunotherapy currently being investigated for treating glioblastoma (NCT04485949). It uses the patient's tumor to elicit an autologous immune response.</p><p><strong>Methods: </strong>The process involves (i) craniotomy for maximum safe resection of the glioblastoma, (ii) <i>ex-vivo</i> treatment of the tumor with an anti-sense oligodeoxynucleotide against insulin-like growth factor 1 receptor followed by irradiation, (iii) placement of the treated tumor in multiple bio-diffusion chambers, which are implanted into the patient's abdominal sheath to elicit an immune response, and (iv) explantation of the chambers 48 hours later. The clinical trial was open at 32 sites in the United States, and eligible subjects were randomized in a 2:1 ratio to receive bio-diffusion chambers containing either conditioned glioblastoma tissue or a placebo. Patients subsequently proceeded to standard-of-care treatment with concomitant radiation-temozolomide, followed by 6 cycles of adjuvant temozolomide.</p><p><strong>Results: </strong>The execution of the IGV-001 protocol procedure is complicated and involves a multi-step process requiring mobilization of multiple services within the cancer center of a tertiary care hospital, including neurosurgery, neuro-oncology, radiation oncology, neuroradiology, cancer clinical trial office, and operating room personnel to fulfill the pre-specified protocol requirements in a timely fashion.</p><p><strong>Conclusions: </strong>We have learned a great deal in the process of developing and executing our internal procedures for this clinical trial. Our description of the IGV-001 protocol workflow may serve as a \"blueprint\" for future implementation of this type of cellular immunotherapy at other centers. We further discuss some of the lessons we have learned during the trial.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1556450"},"PeriodicalIF":3.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of preoperative inflammatory biomarkers on postoperative pneumonia and one-month pulmonary imaging changes after surgery for non-small cell lung cancer.","authors":"Yingding Ruan, Wenjun Cao, Jianwei Han, Aiming Yang, Jincheng Xu, Ting Zhang","doi":"10.3389/fonc.2025.1489068","DOIUrl":"10.3389/fonc.2025.1489068","url":null,"abstract":"<p><strong>Background: </strong>This study examined the effectiveness of preoperative inflammatory markers in predicting the occurrence of postoperative pneumonia (POP) and clinical outcomes based on chest computed tomography (CT) images in patients who underwent surgical resection for non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>This retrospective study included NSCLC patients who underwent lung cancer surgery at The First People's Hospital of Jiande between January 2019 and October 2023. Data on demographic characteristics, preoperative inflammatory biomarkers, surgical approach and duration, postoperative outcomes, and CT findings 1 month postoperatively were collected and analyzed. The effectiveness of preoperative inflammatory markers in predicting POP and clinical outcomes 1 month after surgical resection was assessed using propensity score matching.</p><p><strong>Results: </strong>Among 568 patients, 72 (12.7%) had POP. After matching, 252 patients (POP group: 66; non-POP group: 186) were included in the analysis. The systemic immune-inflammation index (SII) and platelet-to-lymphocyte ratio (PLR) were significantly higher in the POP group than in the non-POP group (433.53 vs. 323.75, <i>P</i> = 0.001; 126.42 vs. 103.64, <i>P</i> < 0.001). The length of hospital stay and the percentage of patients who improved clinically based on chest CT findings 1 month after surgery were significantly higher in the POP group than in the non-POP group (11 days vs. 9 days, <i>P</i> = 0.008; 77.3% vs. 59.7%, <i>P</i> = 0.033). Multivariate analysis showed that PLR and the lymphocyte-to-monocyte ratio (LMR) were independent predictors of POP (AUC of 0.780 and 0.730, both at <i>P</i> < 0.001). However, there were no significant differences in postoperative radiographic outcomes among patients stratified by risk of POP.</p><p><strong>Conclusion: </strong>PLR and LMR accurately predict POP in surgical patients with NSCLC. Nonetheless, these ratios may not significantly predict radiographic outcomes 1 month after surgical resection.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1489068"},"PeriodicalIF":3.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of myelodysplastic syndromes and myeloproliferative neoplasms, 1990-2021: an analysis from the global burden of disease study 2021.","authors":"Xinyue Gou, Zhuo Chen, Yudi Shangguan","doi":"10.3389/fonc.2025.1559382","DOIUrl":"10.3389/fonc.2025.1559382","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the trends and cross-country inequalities in the burden of Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) over the past 30 years and forecast potential changes through 2045.</p><p><strong>Methods: </strong>Estimates and 95% uncertainty intervals (UIs) for incidence, deaths, and disability-adjusted life-years (DALYs) associated with MDS/MPN were obtained from the Global Burden of Diseases (GBD) 2021 database. We described the epidemiology of MDS/MPN at global, regional, and national levels, analyzed trends in the burden of MDS/MPN from 1990 to 2021 through overall, local, and multidimensional perspectives, decomposed the burden based on population size, age structure, and epidemiological changes, quantified cross-country inequalities in MDS/MPN burden using standard health equity methods recommended by the WHO, and predicted changes of MDS/MPN burden to 2045.</p><p><strong>Results: </strong>The global incidence of MDS/MPN has shown a marked increase, escalating from 171,132 cases in 1990 to 341,017 cases in 2021. Additionally, the burden was found to be significantly greater in men compared to women. The overall global burden of MDS/MPN exhibited a consistent increase from 1990 to 2021, although the growth rate showed a noticeable slowdown between 2018 and 2021. Decomposition analysis identified population growth as a key factor influencing the variations in the burden of MDS/MPN. An inequality analysis across countries indicated that high Socio-demographic Index (SDI) countries bore a disproportionate share of the MDS/MPN burden, with significant SDI-related disparities remaining evident. Interestingly, while the incidence and deaths of MDS/MPN, along with the age-standardized rate (ASR) for DALYs, are projected to decline annually from 2020 to 2045, the absolute number of cases for these indicators is expected to continue rising. By 2045, the projected numbers are estimated to reach 457,320 cases for incidence, 82,047 cases for deaths, and 1,689,518 cases for DALYs.</p><p><strong>Conclusions: </strong>As a major public health issue, the global burden of MDS/MPN showed an overall increasing trend from 1990 to 2021, which was primarily driven by population growth and aging. The largest share of the MDS/MPN burden was seen primarily in men, with older demographics. Countries with elevated SDI experienced a significantly higher burden of MDS/MPN. While the burden of MDS/MPN was most pronounced in high SDI quintile, the fastest growth was observed in the low-middle SDI quintile, especially in tropical Latin America. This study highlighted great challenges in the control and management of MDS/MPN, including both growing case number and distributive inequalities worldwide. These findings provide valuable insights for developing more effective public health policies and optimizing the allocation of medical resources.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1559382"},"PeriodicalIF":3.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: a systematic review.","authors":"Sara Dall' Armellina, Gayane Aghakhanyan, Alessio Rizzo, Salvatore C Fanni, Giacomo Aringhieri, Lorenzo Faggioni, Dania Cioni, Emanuele Neri, Duccio Volterrani, Silvia Morbelli","doi":"10.3389/fonc.2025.1553505","DOIUrl":"10.3389/fonc.2025.1553505","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate-Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein initially identified in prostate cancer (PCa) but also expressed in the neovasculature of various solid tumors. Recently, PSMA PET has emerged as a promising tool for detecting brain metastases (BMs) from non-prostatic cancers, offering diagnostic capabilities in addition to conventional imaging. This systematic review evaluates the role of PSMA-targeted radiopharmaceuticals in imaging BMs, highlighting their comparative diagnostic performance and exploring their potential for theranostic applications.</p><p><strong>Methods: </strong>A systematic review of the literature was conducted following PRISMA guidelines. Studies evaluating the diagnostic accuracy of PSMA PET imaging in identifying brain metastases (BMs) from non-prostatic solid tumors were included. Both full research articles and case reports were considered to capture the breadth of current evidence. The methodological quality of the included studies was assessed using the QUADAS-2 tool, and data were synthesized qualitatively.</p><p><strong>Results: </strong>The review includes 23 studies reporting on 77 BMs from diverse primary malignancies, including lung, breast, salivary gland, thyroid, kidney, and melanoma. PSMA PET demonstrated high tumor-to-background ratios (TBR), enabling superior detection of BMs compared to conventional imaging modalities such as contrast-enhanced MRI and [18F]FDG PET. In post-radiotherapy cases, PSMA PET effectively differentiated radionecrosis from tumor recurrence. Moreover, PSMA PET demonstrated superior sensitivity in detecting thyroid metastases compared to traditional scintigraphy methods, highlighting its potential in cases where standard techniques yield inconclusive results.</p><p><strong>Conclusions: </strong>PSMA PET imaging shows significant promise in improving the diagnosis and management of BMs from non-prostatic cancers. While its theranostic applications remain underexplored, initial findings suggest promising avenues for integrating PSMA PET into personalized neuro-oncology care. Future studies should focus on standardizing imaging protocols, exploring PSMA PET utility in diverse tumor subtypes, and validating its role in clinical decision-making to maximize its impact on patient outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1553505"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour habitat-based radiomics analysis enhances the ability to predict prostate cancer aggressiveness with biparametric MRI-derived features.","authors":"Mengjuan Li, Ning Ding, Shengnan Yin, Yan Lu, Yiding Ji, Long Jin","doi":"10.3389/fonc.2025.1504132","DOIUrl":"10.3389/fonc.2025.1504132","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to develop three predictive models utilising clinical factors, radiomics features, and habitat features, to distinguish between nonclinically significant prostate cancer (csPCa) and clinically significant PCa (non-csPCa) on the basis of biparametric MRI (bp-MRI).</p><p><strong>Methods: </strong>A total of 175 patients were enrolled, including 134 individuals with csPCa and 41 with non-csPCa. The clinical model was developed using optimal predictive factors obtained from univariable logistic regression and modelled through a random forest approach. Image acquisition and segmentation were performed first in the creation of both the radiomics model and the habitat model. The K-means clustering algorithm was then used exclusively for habitat generation in the development of the habitat model. Finally, feature selection and model construction were performed for both models. Model comparison and diagnostic efficacy assessment were conducted through receiver operating characteristic curve analysis, decision curve analysis (DCA), and calibration curve analysis.</p><p><strong>Results: </strong>The habitat model outperformed both the radiomics model and the clinical model in distinguishing csPCa from non-csPCa patients. The AUC values of the habitat model in the training and test sets were 0.99 and 0.93, respectively. Furthermore, DCA and the calibration curves highlighted the superior clinical utility and greater predictive accuracy of the habitat model in comparison with the other two models.</p><p><strong>Conclusion: </strong>We developed a habitat-based radiomics model with a greater ability to distinguish between csPCa and non-csPCa on the basis of bp-MRI than a traditional radiomics model and clinical model. This introduces a novel approach for assessing the heterogeneity of PCa and offers urologists a quantitative, noninvasive method for preoperatively evaluating the aggressiveness of PCa.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1504132"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report.","authors":"Ilaria Gandolfini, Martina Manini, Giuseppe Daniele Benigno, Micaela Gentile, Alessandra Palmisano, Danio Somenzi, Letizia Gnetti, Marco Delsante, Benedetta Mordà, Marta D'Angelo, Daniel Salvetti, Enrico Fiaccadori, Sebastiano Buti, Umberto Maggiore","doi":"10.3389/fonc.2025.1506324","DOIUrl":"10.3389/fonc.2025.1506324","url":null,"abstract":"<p><p>We report on the first case of a dual-kidney transplant recipient diagnosed with a metastatic BK polyomavirus-positive clear renal cell carcinoma with sarcomatoid features, which caused extensive vena cava thrombosis. The patient was successfully treated with the immune checkpoint inhibitors (ICIs) ipilimumab plus nivolumab and continued immunosuppression with tacrolimus, mycophenolate, and steroids. He received ICIs despite the presence of graft dysfunction due to transplant glomerulopathy. As expected, the ICI treatment caused a progressive but asymptomatic decline of the graft function, which resulted in end-stage kidney disease. However, continuation of a full immunosuppression prevented acute rejection, graft intolerance syndrome episodes, or dual graft nephrectomy, which enabled the patient to successfully continue ICIs while on dialysis and to achieve sustained partial remission at the 17-month follow-up.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1506324"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: an extremely rare case of giant dedifferentiated retroperitoneal liposarcoma.","authors":"Huey Bing Chua, Rizuana Iqbal Hussain, Nordashima Abd Shukor, Xeng Inn Fam","doi":"10.3389/fonc.2025.1489833","DOIUrl":"10.3389/fonc.2025.1489833","url":null,"abstract":"<p><p>Retroperitoneal liposarcoma, especially dedifferentiated liposarcoma (DDL), is a rare tumor type primarily affecting middle-aged and older adults in the retroperitoneum or proximal extremities. This case report highlights an exceptionally large retroperitoneal DDL that had enveloped the entire right kidney and had adhered to nearby tissues. Diagnosing retroperitoneal liposarcoma is challenging due to its asymptomatic nature until it reaches a substantial size. Imaging, particularly contrast-enhanced computed tomography (CECT), play a vital role in diagnosis, staging, and preoperative planning. Surgical resection, with the goal of R0 resection, remains the cornerstone of treatment, albeit this can be challenging due to tumor location. First-line treatment for advanced DDL involves anthracycline-based therapy. Eribulin and pazopanib show promise in second-line treatment. Ongoing clinical trials suggest a shift towards multimodal therapy. This case report reports the largest retroperitoneal liposarcoma and underscores the complexity of managing retroperitoneal DDL.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1489833"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatics and experimental approach reveal potential prognostic and immunological roles of key mitochondrial metabolism-related genes in cervical cancer.","authors":"Qing Huang, Yang-Feng Xu, Hui-Ping Li, Ting Zhang","doi":"10.3389/fonc.2025.1522910","DOIUrl":"10.3389/fonc.2025.1522910","url":null,"abstract":"<p><strong>Background: </strong>Metabolic remodeling is the hallmark of cancer. In recent years, mitochondrial metabolism (MM) has been considered essential in tumorigenesis and cancer progression. Understanding the role of MM in cervical cancer (CC) can provide insights into disease progression and potential therapeutic targets.</p><p><strong>Methods: </strong>Clinical data of CC patients was downloaded from the UCSC Xena dataset, and differentially expressed genes (DEGs) were identified between tumor and normal samples. MM-related genes (MMRGs) were screened from the MSigDB database. DEGs and MMRGs were then intersected to identify differentially expressed MMRGs. A prognostic risk model was constructed based on these intersecting genes through Cox regression analysis, and its association with the tumor microenvironment and immune checkpoint-related genes was evaluated. Hub genes' expression was evaluated in cells through qRT-PCR. Additionally, drug sensitivity analysis was conducted to explore potential therapeutic drugs.</p><p><strong>Results: </strong>We identified 259 overlapping genes between DEGs and MMRGs, with 55 being prognosis-related. Two molecular clusters were revealed, with C1 exhibiting poorer prognosis. A prognostic risk model comprising five genes (BDH1, MIR210, MSMO1, POLA1, and STARD3NL) was established, showing significant associations with survival outcomes of CC patients. Functional enrichment analysis revealed that DEGs between high- and low-risk groups were tightly associated with the immune system. Analysis of the immune microenvironment showed significant differences between different risk groups, with higher immune and ESTIMATE scores observed in the low-risk group. Additionally, expression levels of immune checkpoint-related genes were significantly correlated with the risk score. Drug sensitivity analysis identified potential therapeutic agents correlated with the expression of the five prognostic genes.</p><p><strong>Conclusion: </strong>Our findings underscore the importance of MM in CC progression and provide potential therapeutic targets for CC.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1522910"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade.","authors":"Yoshiya Ohno, Haruki Okamura, Hideo Yagita, Toshiyuki Tanaka","doi":"10.3389/fonc.2025.1533808","DOIUrl":"10.3389/fonc.2025.1533808","url":null,"abstract":"<p><p>The success of cancer immunotherapy depends on the effective coordination of innate and adaptive immunity. We previously reported that IL-18 potentiates the therapeutic effects of immune checkpoint inhibitors in mouse models. Here, we report that IL-18-primed natural killer (NK) cells enhanced the antitumor effects of anti-PD-1 antibodies by mobilizing type 1 conventional dendritic cells (cDC1s) to tumor sites and promoting type 1 immune responses. IL-18-primed NK cells had a premature phenotype, and expressed chemokines involved in cDC1 mobilization. In a combination treatment with IL-18 and anti-PD-1 antibody, NK cell depletion inhibited cDC1 mobilization and abrogated the therapeutic effects. Additionally, adoptive transfer of IL-18-primed NK cells induced cDC1 mobilization and enhanced the therapeutic effects of anti-PD-1 antibodies. IL-18 also increased IL-12 mRNA expression in DCs and IL-12 blood levels, and IL-12 upregulated XCL1 expression in NK cells. These results suggest that IL-18 primes NK cells and enhances the therapeutic effects of immune checkpoint inhibitors by promoting a feed-forward loop involving DCs.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1533808"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}